logo
Twitter
Discord
Email
logo
Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

NASDAQ•ATOS
CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2012-11-08
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Contact Information
107 Spring Street, Seattle, WA, 98104, United States
206-588-0256
www.atossatherapeutics.com
Market Cap
$79.44M
P/E (TTM)
-2.6
38.2
Dividend Yield
--
52W High
$1.29
52W Low
$0.55
52W Range
9%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.07+21.74%
4-Quarter Trend

FCF

-$6.01M+26.30%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Investment Surge R&D expenses reached $15.0 M for nine months, marking a 40% increase over $10.7 M prior period, supporting clinical programs.
Sufficient Cash Runway Cash and equivalents totaled $51.8 M as of September 30, 2025, providing financing for operations for at least one year.
Clinical Path Progress Received positive FDA feedback on accelerated path for low-dose (Z)-endoxifen risk reduction; IND submission targeted Q4 2025.
Asset Base Reduction Total assets decreased to $58.0 M from $76.4 M year-end, reflecting $23.8 M net loss incurred over the nine months.

Risk Factors

Continued Operating Losses Incurred $23.8 M net loss for nine months; expects ongoing operating losses requiring substantial future capital raises to continue.
Financing Needs Uncertainty Must raise substantial additional capital soon; financing availability or terms are not assured for future operations and development.
Nasdaq Listing Compliance Common stock failed minimum bid price requirement; faces delisting risk if compliance is not regained by February 17, 2026.
Clinical Trial Execution Risk Clinical trial timelines subject to FDA interaction outcomes; potential for delays or failure to demonstrate required efficacy/safety.

Outlook

Metastatic Indication Focus Strategic decision made to pursue metastatic breast cancer indication for lead program (Z)-endoxifen; potential IND submission targeted Q4 2025.
Low-Dose Regulatory Strategy Advancing low-dose (Z)-endoxifen for risk reduction via Type C meeting request with FDA for potential accelerated regulatory path.
Future Funding Requirements Estimated $7.8 M in non-cancellable commitments for clinical trials; future capital needs depend on successful financing efforts.
R&D Spending Continuation R&D expenses increased 40% for nine months, driven by clinical and non-clinical trial costs for the proprietary (Z)-endoxifen program.

Peer Comparison

Revenue (TTM)

Spero Therapeutics, Inc.SPRO
$30.08M
-68.5%
Ovid Therapeutics Inc.OVID
$6.61M
+946.6%
Instil Bio, Inc.TIL
$3.99M
-48.0%

Gross Margin (Latest Quarter)

Spero Therapeutics, Inc.SPRO
100.0%
+0.0pp
Ovid Therapeutics Inc.OVID
87.1%
-12.9pp
Context Therapeutics Inc.CNTX
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MOLN$157.08M-2.0-51.0%1.4%
SPRO$135.78M-3.1-125.9%6.2%
CNTX$132.31M-5.2-30.9%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 24, 2026
|
EPS:-$0.07
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.07+21.7%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.07+35.6%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.05+10.9%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 25, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.20+16.7%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.06+16.2%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.05-38.0%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.05+8.8%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 1, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.24-14.3%
    N/A